Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular, Cowen Ink $40M Stock Sale Deal

NEW YORK (GenomeWeb) — HTG Molecular Diagnostics said after the close of the market on Wednesday that it has signed a sales agreement with Cowen for the sale from time to time of $40 million of HTG's common stock.

The shares will be sold to or through Cowen though HTG is not obligated to sell any shares under the agreement.

HTG said that net proceeds will be used for working capital and general corporate purposes, including capital expenditures and research and development, sales and marketing, and general and administrative expenses. Net proceeds may also be used to fund acquisitions or investments in businesses, products, and technologies that are complementary to HTG's.

Last week, HTG said that it ended 2018 with $8.4 million in cash and cash equivalents and $22.7 million in short-term investments.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.